J&J Wants Changes To Medicare OPPS Rule; Procrit Could Benefit
Executive Summary
Johnson & Johnson is hoping for changes in the proposed 2003 Medicare Outpatient Prospective Payment System that would even out reimbursement differences between Procrit (epoetin) and Amgen's Aranesp (darbepoetin)
You may also be interested in...
Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
The National Cancer Institute will conduct a head-to-head study of Amgen's Aranesp (darbepoetin) and Ortho's Procrit (epoetin) in order to define equivalent doses of the anemia agents, CMS reports in the final Hospital Outpatient Prospective Payment System rule for 2003
Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
The National Cancer Institute will conduct a head-to-head study of Amgen's Aranesp (darbepoetin) and Ortho's Procrit (epoetin) in order to define equivalent doses of the anemia agents, CMS reports in the final Hospital Outpatient Prospective Payment System rule for 2003
Aranesp, Procrit Reimbursement Support Could Raise Kickback Issues – IG
An IG advisory opinion rejecting a proposed patient support program for Aranesp (darbepoetin) helps clarify limits of competition in the chronic renal failure market, Amgen maintains